MYO3B
MOLECULAR TARGETmyosin IIIB
MYO3B (myosin IIIB) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MYO3B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | foretinib | 4.34 | 76 |
| 2 | bosutinib | 4.08 | 58 |
| 3 | bi 2536 | 4.01 | 54 |
| 4 | nintedanib | 3.61 | 36 |
| 5 | tae 684 | 3.43 | 30 |
| 6 | linifanib | 3.33 | 27 |
| 7 | lestaurtinib | 3.04 | 20 |
| 8 | kw 2449 | 2.64 | 13 |
| 9 | ast 487 | 2.56 | 12 |
| 10 | Sorafenib | 0.69 | 1 |
About MYO3B as a Drug Target
MYO3B (myosin IIIB) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented MYO3B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MYO3B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.